CMS Updates Guidelines for Antipsychotic Medication Screening for TD
Discover the latest CMS guidelines urging TD screening for all antipsychotic medication patients to improve diagnosis and patient care.
Discover the latest CMS guidelines urging TD screening for all antipsychotic medication patients to improve diagnosis and patient care.
HealthBridge platform proposes transforming African diaspora remittances into structured health insurance, addressing regulatory, operational, and coordination challenges to strengthen health financing and reduce out-of-pocket costs in Sub-Saharan Africa.
Wisconsin home insurance premiums rose 55% from 2017 to 2024, driven by climate disasters and rising construction costs. Explore regulatory impacts and market trends.
An overview of key issues in U.S. health insurance, FDA regulatory inconsistencies, health care costs, anti-vaccine impacts, and emerging digital health policies affecting public health.
CMS Administrator Dr. Mehmet Oz provides weekly healthy snacking tips to federal employees, highlighting wellness strategies within a major healthcare agency overseeing coverage for 160 million Americans.
Arkansas health insurance enrollees confront premium increases due to ACA subsidy rollbacks in 2026; state regulators implement silver loading to offset costs and maintain coverage affordability. Learn how marketplace shoppers can navigate these changes.
In 2025, U.S. federal regulatory activity hits historic lows under Executive Order 14,192, driving deregulation with a one-in, ten-out rule that reduces net regulatory costs. However, broader federal interventions offset some gains.
ACA marketplace premiums are set to increase by 75% after pandemic-era subsidies expire, risking higher uninsured rates and market instability.
Analysis of federal drug price negotiations under the Inflation Reduction Act, examining perverse incentives in Medicare and private insurance, and exploring Medicare Advantage reforms to improve market efficiency and patient coverage.
The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.